BioSpace News Archive

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that company management will present at three upcoming investor conferences in September.

MIRA Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a novel synthetic THC analog, announced its strategic partnership with MZ Group, a renowned international investor relations firm.

Tris Pharma, Inc. (Tris), today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.

CG Oncology, Inc. announced the appointment of three new members to its executive leadership team: Ambaw Bellete as President and Chief Operating Officer, Swapnil Bhargava, Ph.D. as Chief Technical Officer, and Vijay Kasturi, M.D. as Chief Medical Officer.

Enzolytics, Inc. announced today a continued partnership with Khalpey AI Lab ( https://khalpey-ai.com ) and Contenta, Ltd., Estonia, to identify biomarkers for early onset Alzheimer’s disease.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced an Issue Notification for the Chilean patent 1157-2018 titled “Eflornithine and Sulindac, Fixed Dose Combination Formulation”.

Forge Biologics, a leading manufacturer of genetic medicines, announced today that company leadership will be delivering presentations, participating in fireside chats, and taking one-on-one meetings at four September investor conferences.

IPA, an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated August 9, 2023, it has appointed, in its search for optimal Board composition, Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors of the Company.

Twist Bioscience Corporation today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences.

Guardant Health Receives Regulatory Approval in Japan for Guardant360 ® CDx as Companion Diagnostic to ENHERTU ® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations.